ePrints

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

Lookup NU author(s): Ching Ng, Dr Abul Hasnat, Professor Chris Day, Professor Ann DalyORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens.Twenty-six patients of European or South Asian ethnicity, who had suffered liver injury during treatment with isoniazid-containing drug regimens and 101 ethnically matched controls were genotyped for the NAT2*5, NAT2*6, and NAT2*7 alleles. Genotyping for additional polymorphisms in the NAT gene region was also performed on 20 of the 26 cases. NAT2 genotype frequency between cases and controls was compared.NAT2 genotypes predicting a slow acetylator phenotype were found to be associated with an increased risk of isoniazid-related liver injury (odds ratio (OR) = 4.25 (95 % confidence interval (CI), 1.36-13.22); p = 0.012) with 85 % of the cases being slow acetylators compared with 56 % of the controls. There was no evidence for an increased risk for the slow acetylator genotype in patients with the most severe cases of liver injury, who underwent liver transplantation.The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury. However, the overall effect size is modest and generally in line with effects described previously for this genotype in milder drug-induced liver injury. Additional genetic risk factors may also contribute.

Publication metadata

Author(s): Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, Aithal GP, Daly AK

Publication type: Article

Publication status: Published

Journal: European Journal of Clinical Pharmacology

Year: 2014

Volume: 70

Issue: 9

Pages: 1079-1086

Print publication date: 01/09/2014

Online publication date: 03/06/2014

Acceptance date: 22/05/2014

ISSN (print): 0031-6970

ISSN (electronic): 1432-1041

Publisher: Springer

URL: http://dx.doi.org/10.1007/s00228-014-1703-0

DOI: 10.1007/s00228-014-1703-0

Altmetrics

Funding

Share